Results 241 to 250 of about 294,873 (302)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

INTERNATIONAL BIOLOGICAL STANDARDISATION

open access: yesJournal of Pharmacy and Pharmacology, 1951
openaire   +2 more sources

Procedures of data merging in precision cancer medicine: the PRIME-ROSE project. [PDF]

open access: yesActa Oncol
Van der Pol H   +22 more
europepmc   +1 more source

Patient safety through quality assurance in in-vitro diagnostics - webinar 2024 of the Ad-hoc Commission on In-vitro Diagnostics of the Association of the Scientific Medical Societies in Germany (AWMF). [PDF]

open access: yesGer Med Sci
Vogeser M   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy